PL439226A1 - Kopolimery PAMPS-PAaU do stosowania w leczeniu i/lub profilaktyce infekcji wywołanej przez wirus Zika - Google Patents

Kopolimery PAMPS-PAaU do stosowania w leczeniu i/lub profilaktyce infekcji wywołanej przez wirus Zika

Info

Publication number
PL439226A1
PL439226A1 PL439226A PL43922621A PL439226A1 PL 439226 A1 PL439226 A1 PL 439226A1 PL 439226 A PL439226 A PL 439226A PL 43922621 A PL43922621 A PL 43922621A PL 439226 A1 PL439226 A1 PL 439226A1
Authority
PL
Poland
Prior art keywords
paau
pamps
prophylaxis
treatment
infection caused
Prior art date
Application number
PL439226A
Other languages
English (en)
Other versions
PL245308B1 (pl
Inventor
Maria Nowakowska
Krzysztof PYRĆ
Krzysztof SZCZUBIAŁKA
Paweł BOTWINA
Magdalena Obłoza
Original Assignee
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński filed Critical Uniwersytet Jagielloński
Priority to PL439226A priority Critical patent/PL245308B1/pl
Priority to EP22461623.5A priority patent/EP4166146B1/en
Publication of PL439226A1 publication Critical patent/PL439226A1/pl
Publication of PL245308B1 publication Critical patent/PL245308B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

Przedmiotem zgłoszenia jest kopolimer PAMPS/PAaU o wzorze: gdzie m określa długość bloku PAMPS, a mianowicie liczbę merów AMPS i oznacza liczbę całkowitą od 40 do 170, n określa długość bloku PAaU, a mianowicie liczbę merów AaU i oznacza liczbę całkowitą od 3 do 50, do stosowania w leczeniu i/lub profilaktyce infekcji wywołanej przez wirus Zika.
PL439226A 2021-10-15 2021-10-15 Kopolimery PAMPS-PAaU do stosowania w leczeniu i/lub profilaktyce infekcji wywołanej przez wirus Zika PL245308B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL439226A PL245308B1 (pl) 2021-10-15 2021-10-15 Kopolimery PAMPS-PAaU do stosowania w leczeniu i/lub profilaktyce infekcji wywołanej przez wirus Zika
EP22461623.5A EP4166146B1 (en) 2021-10-15 2022-10-17 Pamps-paau copolymers for use in the treatment or prophylaxis of infection caused by the zika virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL439226A PL245308B1 (pl) 2021-10-15 2021-10-15 Kopolimery PAMPS-PAaU do stosowania w leczeniu i/lub profilaktyce infekcji wywołanej przez wirus Zika

Publications (2)

Publication Number Publication Date
PL439226A1 true PL439226A1 (pl) 2023-04-17
PL245308B1 PL245308B1 (pl) 2024-06-24

Family

ID=84519436

Family Applications (1)

Application Number Title Priority Date Filing Date
PL439226A PL245308B1 (pl) 2021-10-15 2021-10-15 Kopolimery PAMPS-PAaU do stosowania w leczeniu i/lub profilaktyce infekcji wywołanej przez wirus Zika

Country Status (2)

Country Link
EP (1) EP4166146B1 (pl)
PL (1) PL245308B1 (pl)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011020993A (ja) 2009-06-16 2011-02-03 Sekisui Chem Co Ltd Ｒｎａウイルス感染阻止成形用組成物及びｒｎａウイルス感染阻止成形品
WO2017190193A1 (en) * 2016-05-05 2017-11-09 Starpharma Pty Ltd Method of prophylaxis of zika virus infection
PL241834B1 (pl) * 2020-04-03 2022-12-12 Univ Jagiellonski Zastosowanie sulfonowanych pochodnych polistyrenu w leczeniu i/lub profilaktyce infekcji wywołanej przez wirus Zika

Also Published As

Publication number Publication date
EP4166146A1 (en) 2023-04-19
EP4166146A8 (en) 2023-06-28
PL245308B1 (pl) 2024-06-24
EP4166146B1 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
ECSP21080528A (es) Compuestos antivirales que contienen nitrilo
PH12022550286A1 (en) Deuterated compounds for use in the treatment of cancer
MX2022016405A (es) Análogos de nucleósido de 1¿-ciano y usos de estos.
NZ718955A (en) Compositions comprising povidone-iodine
BR112015010919A2 (pt) composição, composição reticulada e artigo
NI200900103A (es) Inhibidores de transcriptasa inversa no nucleosídicos
MX2022013749A (es) Metodos y composiciones para el tratamiento del coronavirus 2 del sindrome respiratorio agudo severo (sars-cov-2).
MY194635A (en) 4'-substituted nucleoside-derivatives as hiv reverse transcriptase inhibitors
MX2019010772A (es) Compuestos heterociclicos utiles como inhibidores dobles de autotaxina (atx)/anhidrasa carbonica (ca).
MX2018003273A (es) Copolimero para usarse como aditivo detergente para combustible.
BR112014016220A8 (pt) composição e artigo
PL399246A1 (pl) Zastosowanie polimeru chitozanowego do leczenia i profilaktyki infekcji wywolanych przez koronawirusy
MX2022008988A (es) Composicion reticulante a base de agua.
EA201692189A1 (ru) Соединения фосфина золота (i) в качестве антибактериальных агентов
GEAP202014873A (en) Methods for treatment and prophylaxis of hiv and aids
MX2023013504A (es) Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1).
MX2023009677A (es) Inhibidores de enzimas.
ECSP21072250A (es) Composiciones basadas en plata coloidal y métodos de uso de ellas para prevenir y controlar las enfermedades de las plantas
JOP20230275A1 (ar) معدلات trex1
MX2021015901A (es) Composiciones oftalmicas.
PH12019502332A1 (en) Treatment of a bacterial vaginal infection
BR112022023135A2 (pt) Amidas tricíclicas substituídas, análogos das mesmas e métodos que usam as mesmas
BR112021026585A2 (pt) Uso de uma composição
CO2022014115A2 (es) Compuestos para su uso en el tratamiento de la infección por coronavirus
PL433443A1 (pl) Zastosowanie sulfonowanych pochodnych polistyrenu w leczeniu i/lub profilaktyce infekcji wywołanej przez wirus Zika